Larotrectinib
Larotrectinib is a targeted anticancer medicine used to treat adult and paediatric patients with locally advanced or metastatic solid tumours that have a confirmed neurotrophic tyrosine receptor kinase (NTRK) gene fusion, when surgery is likely to cause severe complications or no satisfactory alternative treatment is available. It works by selectively inhibiting TRK proteins produced by NTRK gene fusions, blocking abnormal signalling pathways that drive tumour growth. It is available as oral capsules and an oral solution, allowing administration to patients who may have difficulty swallowing capsules. Common side effects include fatigue, dizziness, nausea, vomiting, constipation, and elevated liver enzymes. Important precautions include monitoring liver function, neurological symptoms, and potential drug interactions, as larotrectinib may cause neurotoxicity and liver abnormalities. Treatment should be prescribed by an oncology specialist after molecular confirmation of an eligible NTRK gene fusion.
Larotrectinib was historically used as a respiratory medicine for the symptomatic management of certain respiratory conditions. Its former uses included:
is okay
The import of medicines into India is regulated by the Central Drugs Standard Control Organisation (CDSCO) under the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. The regulatory requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished formulation, or an unapproved medicine intended for an individual patient's treatment.
Primeera Healthcare Private Limited can provide import coordination and pharmaceutical documentation assistance for Larotrectinib, subject to confirmation of its current regulatory status and eligibility for import into India.
The export of Larotrectinib from India is subject to applicable requirements under the Drugs and Cosmetics Act, 1940, the Drugs and Cosmetics Rules, 1945, and relevant export, customs, and destination-country regulations. Documentation requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished pharmaceutical formulation, or a medicine intended for a specific market. Export eligibility and destination-country requirements must be verified before shipment.
Primeera Healthcare Private Limited can provide pharmaceutical export documentation assistance, regulatory coordination, and shipping support for Larotrectinib, subject to confirmation of its export eligibility under applicable Indian regulations and the import requirements of the destination country.
If you have any questions or need any help, contact our Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
All Trademarks and Brands that appear on the website belong to their respective owners. Primeera Healthcare does not lay any claim on them; we only provide information.
